Cerebrospinal fluid α-synuclein in the differential diagnosis of parkinsonian syndromes

Future Neurology

Volumn 9, Issue 5, 2014, Pages 525-532

  Heegaard, Niels H H ^a,b   Tanassi, Julia T ^a   Bech, Sara ^c   Salvesen, Lisette ^c   Jensen, Peter Lüttge ^d   Montezinho, Liliana C P ^e   Winge, Kristian ^c  

^a STATENS SERUM INSTITUT   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c BISPEBJERG HOSPITAL   (Denmark)

^d DANISH TECHNOLOGICAL INSTITUTE   (Denmark)

^e H LUNDBECK A S   (Denmark)

Author keywords

biomarker; Parkinson's disease; spinal fluid; synuclein

Indexed keywords

ALPHA SYNUCLEIN; TAU PROTEIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORTICOBASAL DEGENERATION; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PARKINSONISM; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN CEREBROSPINAL FLUID LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SHY DRAGER SYNDROME;

EID: 84908319093     PISSN: 14796708     EISSN: 17486971     Source Type: Journal    
DOI: 10.2217/fnl.14.51     Document Type: Article

References (45)

1. Gilman S, Wenning GK, Low PA et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71(9), 670-676 (2008
2. Litvan I, Agid Y, Calne D et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele- Richardson-Olszewski syndrome): report of the NINDS-SPSP International Workshop. Neurology 47(1), 1-9 (1996
3. McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J. Alzheimers Dis. 9(3 Suppl.), 417-423 (2006
4. Armstrong MJ, Litvan I, Lang AE et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 80(5), 496-503 (2013
5. Braak H, Rub U, Sandmann-Keil D et al. Parkinson's disease: affection of brain stem nuclei controlling premotor and motor neurons of the somatomotor system. Acta Neuropathol. (Berl). 99(5), 489-495 (2000
6. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del TK. Stages in the development of Parkinson's disease-related pathology. Cell. Tissue Res. 318(1), 121-134 (2004
7. Iranzo A, Valldeoriola F, Lomena F, Molinuevo JL, Serradell M, Salamero M et al. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol. 10(9), 797-805 (2011
8. Agid Y, Ahlskog E, Albanese A et al. Levodopa in the treatment of Parkinson's disease: a consensus meeting. Mov. Disord. 14(6), 911-913 (1999
9. Fahn S, Oakes D, Shoulson I et al. Levodopa and the progression of Parkinson's disease. N. Engl. J. Med. 351(24), 2498-2508 (2004
10. Olanow CW, Rascol O, Hauser R et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N. Engl. J. Med. 361(13), 1268-1278 (2009
11. Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rub U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J. Neurol. 249(Suppl. 3), III/1-5 (2002
12. Svenningsson P, Westman E, Ballard C, Aarsland D. Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. Lancet Neurol. 11(8), 697-707 (2012
13. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch. Neurol. 56(1), 33-39 (1999
14. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 388(6645), 839-840 (1997
15. Marques O, Outeiro TF. Alpha-synuclein: from secretion to dysfunction and death. Cell Death Dis. 3, e350 (2012
16. Fauvet B, Mbefo MK, Fares MB et al. Alpha-synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J. Biol. Chem. 287(19), 15345-15364 (2012
17. Tokuda T, Salem SA, Allsop D et al. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem. Biophys. Res. Commun. 349(1), 162-166 (2006
18. El-Agnaf OM, Salem SA, Paleologou KE et al. Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J. 17(13), 1945-1947 (2003
19. Dubois B, Feldman HH, Jacova C et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 6(8), 734-746 (2007
20. Mollenhauer B, Cullen V, Kahn I et al. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp. Neurol. 213(2), 315-325 (2008
21. Hong Z, Shi M, Chung KA et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 133(Pt 3), 713-726 (2010
22. Aerts MB, Esselink RA, Abdo WF, Bloem BR, Verbeek MM. CSF alpha-synuclein does not differentiate between parkinsonian disorders. Neurobiol. Aging 33(2), 430-433 (2012
23. Kasuga K, Nishizawa M, Ikeuchi T. Alpha-synuclein as CSF and blood biomarker of dementia with Lewy bodies. Int. J. Alzheimers Dis. 2012, 437025 (2012
24. Parnetti L, Castrioto A, Chiasserini D et al. Cerebrospinal fluid biomarkers in Parkinson disease. Nat. Rev. Neurol. 9(3), 131-140 (2013
25. Taira T, Saito Y, Niki T, Iguchi-Ariga SM, Takahashi K, Ariga H. DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep. 5(2), 213-218 (2004
26. Polymeropoulos MH, Lavedan C, Leroy E et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276(5321), 2045-2047 (1997
27. Lucking CB, Brice A. Alpha-synuclein and Parkinson's disease. Cell Mol. Life Sci. 57(13-14), 1894-1908 (2000
28. Lucking CB, Durr A, Bonifati V et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. N. Engl. J. Med. 342(21), 1560-1567 (2000
29. Chahine LM, Stern MB. Diagnostic markers for Parkinson's disease. Curr. Opin. Neurol. 24(4), 309-317 (2011
30. Salvesen L, Bech S, Lokkegaard A et al. The DJ-1 concentration in cerebrospinal fluid does not differentiate among Parkinsonian syndromes. Parkinsonism Relat. Disord. 18(7), 899-901 (2012
31. Foulds PG, Yokota O, Thurston A et al. Post mortem cerebrospinal fluid alpha-synuclein levels are raised in multiple system atrophy and distinguish this from the other alpha-synucleinopathies, Parkinson's disease and dementia with Lewy bodies. Neurobiol. Dis. 45(1), 188-195 (2012
32. Bech S, Hjermind LE, Salvesen L et al. Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes. Parkinsonism Relat. Disord. 18(1), 69-72 (2012
33. Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson's disease. Ann. Neurol. 32(Suppl.), S125-S127 (1992
34. Litvan I, Bhatia KP, Burn DJ et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov. Disord. 18(5), 467-486 (2003
35. Hirotani M, Maita C, Niino M, Iguchi-Ariga S, Hamada S, Ariga H et al. Correlation between DJ-1 levels in the cerebrospinal fluid and the progression of disabilities in multiple sclerosis patients. Mult. Scler. 14(8), 1056-1060 (2008
36. Hulstaert F, Blennow K, Ivanoiu A et al. Improved discrimination of AD patients using beta-amyloid (1-42) and tau levels in CSF. Neurology 52, 1555-1562 (1999
37. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 57(8), 1497-1499 (2001
38. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125(Pt 4), 861-870 (2002
39. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, Schlossmacher MG. Alpha-synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 10(3), 230-240 (2011
40. Mollenhauer B, Trautmann E, Taylor P et al. Total CSF alpha-synuclein is lower in de novo Parkinson patients than in healthy subjects. Neurosci. Lett. 532, 44-48 (2013
41. Wennstrom M, Londos E, Minthon L, Nielsen HM. Altered CSF orexin and alpha-synuclein levels in dementia patients. J. Alzheimers Dis. 29(1), 125-132 (2012
42. Aerts MB, Esselink RA, Claassen JA, Abdo WF, Bloem BR, Verbeek MM. CSF tau, Abeta42, and MHPG differentiate dementia with Lewy bodies from Alzheimer's disease. J. Alzheimers Dis. 27(2), 377-384 (2011
43. van Geel WJ, Abdo WF, Melis R, Williams S, Bloem BR, Verbeek MM. A more efficient enzyme-linked immunosorbent assay for measurement of alpha-synuclein in cerebrospinal fluid. J. Neurosci. Methods 168(1), 182-185 (2008
44. Parnetti L, Chiasserini D, Bellomo G et al. Cerebrospinal fluid Tau/alpha-synuclein ratio in Parkinson's disease and degenerative dementias. Mov. Disord. 26(8), 1428-1435 (2011
45. Tokuda T, Qureshi MM, Ardah MT et al. Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75(20), 1766-1772 (2010